NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Pres
Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in tough-to-treat HNSCC populationOral presentation by Dr. Tanguy Y. Seiwert with comprehensive review of local and systemic potential effects of NBTXR3...
Source: pharmiweb.com